Chinese Drugmakers Target Expiring U.S. Patents
Imitating their Indian counterparts, the Chinese firms view acquiring expiring life-sciences technology and over-the-counter drug patents from U.S. companies a more time-efficient option than developing new drugs.
U.S. makers of branded drugs have hesitated to enter the Chinese market given the widespread intellectual property rights violations in the country.
Last week, international agencies including WHO began a three-day meeting in Hanoi to try to...
To view the full article, register now.